Phase 4 N=198 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
Schizophrenia
Primary: Percentage of Participants That Responded to Treatment — 62.8; 56.8 percentage of response — p=.61
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Patient Noncompliance
Primary: Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks — 6.50; 9.85 days
Phase 4 N=60 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03
N/A N=63 Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity
Schizophrenia
Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale
N/A N=733 Safer Use of Antipsychotics in Youth
Child Behavior Disorders
Primary: Percent of Youths With Antipsychotic Orders at 6 Months — 54.6; 47.6 percentage of youths
Phase 4 N=21 Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
Schizophrenia
Primary: Feasibility of Randomizing a Cohort of Participants Meeting the Inclusion and Exclusion Criteria of the Study — 21 participants
Phase 4 N=491 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia
Schizophrenia
Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…
Phase 2 N=90 Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
Parkinson's Disease · Psychotic Disorders
Primary: Patient Evaluation of Symptoms of Psychosis. — -9.8; -12.9; -9.7; -10.0 Scores on a scale — p=0.5177
N/A N=11 Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers
Imaging of the Brain and Antipsychotics · Neuronal Network Changes
Primary: Repeatable Battery for the Assessment of Neuropsychological Status — -1.5; -0.5 RBANS T-Scale point difference
Phase 4 N=85 A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 104 or Last Reported Visit (LRV) — 80.6; 79.7; -18.1; -17.7 Units on a scale
Phase 4 N=22 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
Eating Disorders
Primary: Change From Baseline in Weight (Lbs.) at 12 Weeks — 2.2; -1.2 lbs
Phase 3 N=187 Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)
Schizophrenia
Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants
Phase 4 N=53 Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
Schizophrenia
Primary: Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2 — 55.53 Units on a scale
Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Phase 3 N=452 A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 92 or Early Withdrawal — 82.1; 84.4; -23.6; -26.9 Units on scale
Phase 3 N=323 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…
Phase 3 N=8 Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
Schizophreniform Disorder · Schizoaffective Disorder · Psychosis
Primary: Weight Gain and Other Side Effects
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
Phase 3 N=208 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Dementia, Alzheimer Type
Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802
Phase 4 N=190 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 48 — 11.57; 6.43; 16.36 Units on a scale
Phase 3 N=764 Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
Schizophrenia
Primary: Time to First Relapse Event — 616; 603 days — p=0.0191
Phase 3 N=228 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935
Phase 4 N=10 The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
Healthy
Primary: Change in Brain Nicotinamide Adenine Dinucleotide Metabolites NAD+/NADH — -0.79 ratio
Phase 4 N=133 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13 — 88.98; 22.468 units on a scale
N/A N=10 Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade
Schizophrenia
Primary: Working Memory — 44.8 units on a scale
Phase 3 N=403 A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 — 77.18; 58.46; 63.33; -26.29 unit on a scale
Phase 4 N=110 Antipsychotic Discontinuation in Alzheimer's Disease
Alzheimer Disease · Psychotic Disorders · Agitation
Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02
Phase 4 N=72 A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
Agitation
Primary: Change in the PANSS-EC Score Among Participants From Baseline to 2 Hours After Administration of the Medication. — -11.0; -11.5 score on a scale — p=>0.05
Phase 2 N=34 Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: Yale Brown Obsessive Compulsive Scale — 19.14; 21.24 Scores on a scale — p=<0.05
Phase 2 N=334 Study of a Novel Antipsychotic ITI-007 in Schizophrenia
Schizophrenia
Primary: Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score — -13.2; -8.3; -7.4; -13.4 score on a scale — p=0.017